Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 1.

Citations Over TimeTop 14% of 2004 papers

Abstract

We have used a structure-based approach to design a novel series of non-nucleoside inhibitors of HIV-1 RT (NNRTIs). Detailed analysis of a wide range of crystal structures of HIV-1 RT-NNRTI complexes together with data on drug resistance mutations has identified factors important for tight binding of inhibitors and resilience to mutations. Using this approach we have designed and synthesized a novel series of quinolone NNRTIs. Crystal structure analysis of four of these compounds in complexes with HIV-1 RT confirms the predicted binding modes. Members of this quinolone series retain high activity against the important resistance mutations in RT at Tyr181Cys and Leu100Ile.

Related Papers

• → Endochin Optimization: Structure−Activity and Structure−Property Relationship Studies of 3-Substituted 2-Methyl-4(1H)-quinolones with Antimalarial Activity(2010)101 cited
• → Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses(2013)99 cited
• → Design of Annulated Pyrazoles as Inhibitors of HIV-1 Reverse Transcriptase(2008)74 cited
• → Structural modifications of quinolone-3-carboxylic acids with anti-HIV activity(2011)15 cited
• Structure-activity relationship of quinolone antibacterial agents: the effects of C-2 substitution.(1990)